- Home
- JCTC vs NERV Comparison
JCTC vs NERV Comparison
Compare JCTC & NERV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- JCTC
- NERV
- Stock Information
- Founded
- JCTC 1953
- NERV 2007
- Country
- JCTC United States
- NERV United States
- Employees
- JCTC N/A
- NERV N/A
- Industry
- JCTC
- NERV Biotechnology: Pharmaceutical Preparations
- Sector
- JCTC
- NERV Health Care
- Exchange
- JCTC NYSE
- NERV Nasdaq
- Market Cap
- JCTC 13.2M
- NERV 12.0M
- IPO Year
- JCTC 1996
- NERV 2014
- Fundamental
- Price
- JCTC $3.49
- NERV $1.91
- Analyst Decision
- JCTC
- NERV Hold
- Analyst Count
- JCTC 0
- NERV 1
- Target Price
- JCTC N/A
- NERV $5.00
- AVG Volume (30 Days)
- JCTC 16.7K
- NERV 21.2K
- Earning Date
- JCTC 07-14-2025
- NERV 08-05-2025
- Dividend Yield
- JCTC N/A
- NERV N/A
- EPS Growth
- JCTC N/A
- NERV N/A
- EPS
- JCTC N/A
- NERV 0.83
- Revenue
- JCTC $44,141,421.00
- NERV N/A
- Revenue This Year
- JCTC N/A
- NERV N/A
- Revenue Next Year
- JCTC N/A
- NERV N/A
- P/E Ratio
- JCTC N/A
- NERV $2.36
- Revenue Growth
- JCTC N/A
- NERV N/A
- 52 Week Low
- JCTC $3.26
- NERV $1.15
- 52 Week High
- JCTC $5.41
- NERV $3.30
- Technical
- Relative Strength Index (RSI)
- JCTC N/A
- NERV 51.36
- Support Level
- JCTC N/A
- NERV $1.94
- Resistance Level
- JCTC N/A
- NERV $2.32
- Average True Range (ATR)
- JCTC 0.00
- NERV 0.16
- MACD
- JCTC 0.00
- NERV 0.00
- Stochastic Oscillator
- JCTC 0.00
- NERV 41.73
About JCTC JEWETT-CAMERON TRADING CO
Jewett-Cameron Trading Co Ltd through its subsidiaries engages in the wholesale distribution of a variety of specialty wood products. Its operating segments include, The Industrial wood products segment is engaged in the processing and distribution of industrial wood products. The Pet Fencing and Other segment, which is the key revenue driver, operates as a wholesaler of wood products and a manufacturer and distributor of specialty metal products. The Seed processing and sales segment processes and distributes agricultural seed and Corporate and administrative. The company predominantly operates in the United States and also has a presence in Canada, Latin America, Europe and Asia Pacific, and other regions.
About NERV Minerva Neurosciences Inc
Minerva Neurosciences Inc is a clinical-stage biopharmaceutical company. It focuses on the development and commercialization of a portfolio of product candidates to treat patients suffering from central nervous system diseases. The company's pipeline products include MIN-101, MIN-202, and MIN-301. Targeted disorders include schizophrenia, insomnia, depressive disorder, and Parkinson's disease. Its product portfolio and potential indications include Roluperidone for the treatment of negative symptoms in patients with schizophrenia; Seltorexant, for the treatment of insomnia disorder and depressive disorder; MIN-117 for the treatment of MDD; and MIN-301 for the treatment of Parkinson's disease.